Tevimbra (tislelizumab-jsgr) — Medica
Esophageal and Esophagogastric Junction Cancers
Initial criteria
- age ≥ 18 years
- unresectable locally advanced, recurrent, or metastatic disease
- ONE of the following: (i) esophageal squamous cell carcinoma AND ALL of: PD-L1 combined positive score ≥ 1 by approved test, used as first-line or induction therapy, used in combination with chemotherapy; OR (ii) esophageal squamous cell carcinoma AND BOTH of: used as single agent, used for subsequent therapy; OR (iii) esophageal adenocarcinoma AND BOTH of: HER2 overexpression negative disease, PD-L1 combined positive score ≥ 1
- ONE of the following: patient has not previously received a checkpoint inhibitor OR no tumor progression while on a checkpoint inhibitor
- prescribed by or in consultation with an oncologist
Approval duration
1 year